论文部分内容阅读
目的 :研究ProMACE/CytaBOM方案治疗中、高度恶性非霍奇金淋巴瘤的临床疗效及不良反应。方法 :采用ProMACE/CytaBOM方案治疗非霍奇金淋巴瘤 34例。其中弥漫性大细胞型 2 1例 ,弥漫性小裂细胞型 3例 ,弥漫性大小细胞混合型 4例 ,免疫母细胞型 3例 ,淋巴母细胞型 2例 ,小无裂细胞型1例。恶性程度为中高度。分期为Ⅱ～Ⅳ期。结果 :CR 2 3例 ,占 67.6% ;PR 6例 ,占 17.6% ;有效率为85.3%。主要毒副作用为骨髓抑制和胃肠道反应。结论 :ProMACE/CyatBOM方案治疗中高度恶性非霍奇金淋巴瘤近期疗效确切 ,毒副作用可耐受 ,值得临床推广。
Objective: To study the clinical efficacy and adverse reactions of ProMACE/CytaBOM regimen in the treatment of high-grade malignant non-Hodgkin’s lymphoma. Methods: Thirty-four cases of non-Hodgkin’s lymphoma were treated with ProMACE/CytaBOM regimen. There were 21 cases of diffuse large cell type, 3 cases of diffuse small split cell type, 4 cases of diffuse size cell mixed type, 3 cases of immunoblastic type, 2 cases of lymphoblastoid type, and 1 case of small non-cleaved type. The degree of malignancy is medium height. The staging is a period of II to IV. Results: There were 3 cases of CR (67.6%), 6 cases of PR (17.6%), and the effective rate was 85.3%. The main toxic side effects are myelosuppression and gastrointestinal reactions. Conclusion : The ProMACE/CyatBOM regimen is effective for the treatment of moderately-advanced non-Hodgkin’s lymphoma. The toxic and side effects are tolerable and worthy of clinical promotion.